The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas

Jelicic, Jelena; Balint, Milena Todorovic; Jovanović, Marina; Boričić, Novica; Micev, Marjan; Stojšić, Jelena; Andjelic, Bosko; Bila, Jelena; Balint, Bela; Pavlović, Sonja; Mihaljević, Biljana

doi:10.1007/s12253-015-0032-7

Cited by 9 publications

(15 citation statements)

References 46 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have previously published data to show that low lymphocyte count is significantly associated with adverse outcomes [ 15 ]. Similar findings and other parameters of high monocytes and decreased lymphocyte/monocyte ratio have also been found to be associated with poor prognosis [ 16 – 20 ]. Low levels of CD4+ T cells appear to be an independent predictor of inferior survival [ 21 ].…”

Section: Introductionsupporting

confidence: 78%

High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(−/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma

et al. 2020

View full text Add to dashboard Cite

Background Diffuse large B cell lymphoma (DLBCL) is the commonest lymphoma that is highly aggressive where one-third of the patients relapse despite effective treatment. Interaction between the lymphoma cells and the non-clonal immune cells within the bone marrow microenvironment is thought to play a critical role in the pathogenesis of DLBCL. Methods We used flow cytometry to characterize the proportion of B cell subpopulations in the bone marrow (N = 47) and peripheral blood (N = 54) of 75 DLBCL patients at diagnosis and study their impact on survival. Results Anergic B cells in the bone marrow (BM), characterized as having CD21(−/low)/CD38- expression, influenced survival with high numbers (defined as > 13.9%) being associated with significantly shorter overall survival (59.7 months vs 113.6 months, p = 0.0038). Interestingly, low numbers of anergic B cells in the BM (defined as ≤13.9%) was associated with germinal center B cell type of DLBCL (p = 0.0354) that is known to have superior rates of survival when compared to activated B cell type. Finally, Cox regression analysis in our cohort of patients established that the inferior prognosis of having high numbers of anergic B cells in the bone marrow was independent of the established Revised International Prognostic Index (R-IPI) score. Conclusions High proportion of anergic B cells in the BM characterized by CD21(−/low)/CD38- expression predicts poor survival outcomes in DLBCL.

show abstract

Section: Introductionsupporting

confidence: 78%

High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(−/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The MVD and VEGF levels in non‐Hodgkin's lymphoma (NHL) patients are associated with histological grade, clinical stage, and outcomes . Data on angiogenesis in HL patients are limited to a few reports on VEGF expression and MVD .…”

Section: Discussionmentioning

confidence: 99%

“…32 The MVD and VEGF levels in non-Hodgkin's lymphoma (NHL) patients are associated with histological grade, clinical stage, and outcomes. 15,[33][34][35][36] Data on angiogenesis in HL patients are limited to a few reports on VEGF expression and MVD. [37][38][39] In our present study, we found that high MVD was associated with poorer clinical outcomes, but a higher VEGF expression level was not.…”

Section: Discussionmentioning

confidence: 99%

Epstein‐Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma

Koh

Han

Yoon

et al. 2017

Hematological Oncology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is a significant contributor to the development of classical Hodgkin's lymphoma (cHL). Recent studies have documented associations between angiogenesis and EBV-associated malignancies. No study has yet examined the associations among, and prognostic implications of, EBV infection, vascular endothelial growth factor (VEGF) expression, and microvessel density (MVD) in cHL patients. Diagnostic tissues from 135 cHL patients treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) were retrospectively evaluated by in situ hybridization of EBV-encoded small RNA (EBER) and immunohistochemical staining for VEGF and CD31 (a measure of MVD). EBER and VEGF expression were positively correlated (P = 0.038). The mean MVD value of EBER-positive tumors was significantly higher than that of EBER-negative tumors (P = 0.034). The mean MVD of tumors positive for both EBER and VEGF was significantly higher than that of tumors negative for both markers (P = 0.008). EBER-positive patients had a lower 5-year overall survival (OS) rate than EBER-negative patients (P = 0.046). A high MVD was also associated with a poorer OS (P = 0.01); multivariate analysis showed that this was a significant and independent prognostic factor (P = 0.026). We found positive correlations between EBER and VEGF levels, and the MVD, indicating that EBV plays an important role in tumor angiogenesis. Targeting of both angiogenesis and EBV may be important when treating cHL patients who are EBER-positive and/or have a high MVD.

show abstract

“…25 A number of studies have revealed a positive relationship between CD44 expression and microvessel density (MVD), which is a characteristic of angiogenesis, in human tumor samples. 35,36,38,[54][55][56][57][58][59][60] A parallel increase in CD44 expression and high MVD has been observed in a variety of cancer types, such as infiltrating ductal carcinoma, 38 renal cell carcinoma, 56 and oral squamous cell carcinoma 35 (summarized in Table 1). In the oral orthotopic carcinogenesis mouse model, CD44 expression becomes upregulated in perivascular area along with excessive blood vessel formation during cancer progression.…”

Section: Cd44 In Tumor Angiogenesismentioning

confidence: 99%

The role of CD44 in pathological angiogenesis

Chen

Zhang

et al. 2020

FASEB j.

View full text Add to dashboard Cite

Angiogenesis is required for normal development and occurs as a pathological step in a variety of disease settings, such as cancer, ocular diseases, and ischemia. Recent studies have revealed the role of CD44, a widely expressed cell surface adhesion molecule, in promoting pathological angiogenesis and the development of its associated diseases through its regulation of diverse function of endothelial cells, such as proliferation, migration, adhesion, invasion, and communication with the microenvironment. Conversely, the absence of CD44 expression or inhibition of its function impairs pathological angiogenesis and disease progression. Here, we summarize the current understanding of the roles of CD44 in pathological angiogenesis and the underlying cellular and molecular mechanisms.

show abstract

The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas

Cited by 9 publications

References 46 publications

High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(−/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma

High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(−/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma

Epstein‐Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma

The role of CD44 in pathological angiogenesis

Contact Info

Product

Resources

About